HBM Healthcare Investments Reports CHF 272 Million Profit

HBM Healthcare Investments AG achieved a profit of CHF 272 million in its 25th financial year ending 31 March 2026. The company's net asset value (NAV) per share rose by 17.2%, while the share price saw a significant increase of 28.5%. However, the strong Swiss franc reduced performance by approximately 10%.

The year witnessed a revival in merger and acquisition activity, enhancing portfolio performance. This resulted in a CHF 123 million contribution from private companies, including a capital gain from the sale of Swixx BioPharma to SK Capital Partners. Public investments added CHF 194 million, driven by acquisitions and positive clinical results.

During the year, HBM Healthcare made three new investments totaling CHF 46 million in private companies. With a balanced asset allocation and positive market outlook, the company proposed a CHF 9.00 dividend, yielding 4%.